---
title: Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory
  Indolent Non-Hodgkin Lymphoma (ZUMA-5)
date: '2023-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37879047/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231026180809&v=2.17.9.post6+86293ac
source: Blood
description: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell
  therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval
  was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel in
  patients with R/R indolent non-Hodgkin lymphoma (iNHL; N=104), including FL and
  marginal zone lymphoma (MZL). In the primary analysis (17.5 months median follow-up),
  overall response rate (ORR) was 92% (74% complete response rate). Here we report
  long-term ...
disable_comments: true
---
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel in patients with R/R indolent non-Hodgkin lymphoma (iNHL; N=104), including FL and marginal zone lymphoma (MZL). In the primary analysis (17.5 months median follow-up), overall response rate (ORR) was 92% (74% complete response rate). Here we report long-term ...